Aptinyx Inc. (APTX)
(Delayed Data from NSDQ)
$3.78 USD
+0.03 (0.80%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.79 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.78 USD
+0.03 (0.80%)
Updated May 3, 2019 04:00 PM ET
After-Market: $3.79 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Editas (EDIT) Q1 Earnings Top, Pipeline in Focus, Stock Up
by Zacks Equity Research
Editas Medicine (EDIT) stock climbs 12% on Friday and 7% in the pre-market hours today, after the company beat estimates for both earnings and revenues in first-quarter 2023. Pipeline progress in focus.
McKesson (MCK) to Report Q4 Earnings: Is a Beat in Store?
by Zacks Equity Research
McKesson's (MCK) fiscal fourth-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
Ultragenyx (RARE) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Ultragenyx Pharmaceutical's (RARE) first-quarter 2023 earnings and revenues miss estimates. The company maintains its 2023 guidance.
Blueprint's (BPMC) Q1 Earnings & Sales Top Estimates, View Up
by Zacks Equity Research
Blueprint Medicines (BPMC) announces better-than-expected results for first-quarter 2023 as it beats estimates for both earnings and revenues. Stock surges 13% following the news.
DaVita (DVA) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
High labor costs and inflationary pressures are likely to have weighed on DaVita's (DVA) first-quarter top line.
Novo Nordisk (NVO) Q1 Earnings In Line, Sales Miss, View Up
by Zacks Equity Research
Novo Nordisk (NVO) reports decent first-quarter results as earnings match estimates but sales miss the same. Sales benefit from growth in Diabetes and Obesity Care on higher GLP-1 and Wegovy revenues.
Deciphera (DCPH) Q1 Earnings Match Estimates, Sales Miss
by Zacks Equity Research
Deciphera Pharmaceuticals (DCPH) reports mixed first-quarter 2023 results as its earnings are in line with the Zacks Consensus Estimate, while revenues miss the same.
Horizon (HZNP) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Horizon Therapeutics (HZNP) reports lower-than-expected first-quarter 2023 results as it misses the Zacks Consensus Estimates for both revenues and earnings.
Intra-Cellular's (ITCI) Caplyta Aids Sales, Overreliance a Woe
by Zacks Equity Research
Intra-Cellular (ITCI) is witnessing growth aided by its sole-marketed drug, Caplyta. However, the lack of other promising candidates in the pipeline is concerning.
Bellus Health (BLU) Stock Up 99% on $2B Buyout Offer From GSK
by Zacks Equity Research
Bellus Health (BLU) gets an offer to be acquired by pharma bigwig, GSK for an approximate total equity value of $2 billion. The stock is up 99%, following the news.
Anixa (ANIX) Falls 25% Despite Positive Breast Cancer Study Data
by Zacks Equity Research
Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.
Agenus (AGEN) Rises on Fast Track Tag for Cancer Combo Drug
by Zacks Equity Research
The FDA grants Fast Track Designation to Agenus' (AGEN) phase II study evaluating the botensilimab/balstilimab combination in non-MSI-H colorectal cancer patients. The stock jumps 16% following the news.
Prometheus (RXDX) Stock Surges 70% on Buyout Offer From Merck
by Zacks Equity Research
Prometheus (RXDX) is set to be acquired by Merck for $11 billion, adding Prometheus' lead product candidate, PRA023, to Merck's portfolio. Prometheus' stock is up 70%.
Aeglea (AGLE) Plunges 26% After Rare Disorder Drug Study Fails
by Zacks Equity Research
Aeglea BioTherapeutics (AGLE) announces failure to meet goals in the phase I/II study of pegtarviliase for the treatment of Classical Homocystinuria. The stock is down 26% following the news.
Adaptimmune (ADAP) Up 7%, Gets T-Cell Programs Rights From GSK
by Zacks Equity Research
Adaptimmune Therapeutics (ADAP) enters into a transition deal with GSK to regain rights to its proprietary T-cell therapy programs. Shares of the company surges 7% following the news.
Horizon's (HZNP) Tepezza Meets Goals in TED Expanded Use Study
by Zacks Equity Research
Horizon Therapeutics (HZNP) announces positive top-line data from its phase IV study of Tepezza to expand its indication to include TED in adult patients with chronic/low clinical activity scores.
Merck (MRK) Keytruda Studies in Difficult-to-Treat Cancers Fail
by Zacks Equity Research
Merck (MRK) and Eisai announce the discontinuation of the phase III LEAP-003 study seeking approval of the Keytruda and Lenvima combo. Another phase III LEAP-017 study fails to meet goals.
Here's Why You Should Add Acadia (ACAD) Stock to Your Portfolio
by Zacks Equity Research
Acadia (ACAD), a top-ranked stock at present, is witnessing steady growth in Nuplazid sales since its launch. The newly approved drug, Daybue, is set to provide an incremental stream of revenues.
Aeterna (AEZS) Falls 5% on US Sales Halt of Growth Hormone Drug
by Zacks Equity Research
Aeterna Zentaris (AEZS) announces halting sales of adult growth hormone deficiency diagnosis drug, Macrilen, in the United States in the absence of a commercialization partner. Stock down 5%.
Phathom (PHAT) Up 8% on Erosive Esophagitis Drug's CRL Update
by Zacks Equity Research
Phathom Pharmaceuticals (PHAT) announces a regulatory update regarding vonoprazan for the treatment of erosive esophagitis and H. pylori infection. Stock surges 8% following the news.
Seagen's (SGEN) Padcev & Keytruda Combo Gets FDA Accelerated Nod
by Zacks Equity Research
The FDA grants accelerated approval to Seagen (SGEN) and partner, Astellas' combination therapy of Padcev with Merck's Keytruda for the treatment of first and second-line metastatic urothelial cancer.
Apellis (APLS) Kindles Acquisition Interest Per Bloomberg
by Zacks Equity Research
Per a Bloomberg article, Apellis Pharmaceuticals (APLS) is considering a possible buyout by larger pharma companies.
Avidity (RNA) Down on Update From Neuromuscular Disease Study
by Zacks Equity Research
Avidity Biosciences (RNA) provides an update on its phase I/II study of its lead product candidate AOC 1001 for the treatment of myotonic dystrophy type I. The stock falls about 17%.
Here's Why Aptinyx Inc. (APTX) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Aptinyx Inc. (APTX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up
by Zacks Equity Research
Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.